Skip to search formSkip to main contentSkip to account menu

EndoTAG-1

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Effect of antitumor treatments on triple-negative breast cancer patients
Background: Triple-negative breast cancer (TNBC) lacks the expression of the estrogen receptor, progesterone receptor, and… 
2016
2016
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
Background EndoTAG-1, a tumor endothelial targeting agent has shown activity in metastatic triple-negative breast cancer (BC) in… 
2016
2016
Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial.
4526 Background: EndoTAG-1 is a novel cationic liposomal formulation of paclitaxel being developed for the treatment of solid… 
2014
2014
Dynamische Monitoringverfahren der Perfusionseffekte einer antivaskulären Targettherapie mit EndoTAG-1 bei Kopf-Hals-Karzinomen
Review
2012
Review
2012
Clinical development of new formulations of cytotoxics in solid tumors
Purpose of review To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of… 
2010
2010
The way forward in treating pancreatic cancer
The statistics are familiar to us all. In the United States, 42,470 men and women will be diagnosed with, and 35,240 men and… 
2009
2009
Gateways to clinical trials.
(+)-Dapoxetine hydrochloride; Abatacept, Adalimumab, Agalsidase beta, Alemtuzumab, Alglucosidase alfa, Aliskiren fumarate… 
2008
2008
Targeted Liposomal Paclitaxel Raises Tumor Vessel Leakiness
2008
2008
Encouraging results with EndoTAG-1 in pancreatic cancer
  • 2008
  • Corpus ID: 195104826
2005
2005
EndoTAG-1. MediGene.
MediGene is developing EndoTAG-1, a formulation of paclitaxel encapsulated in positively charged lipid-based complexes, for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)